UNASSIGNED: In recent years, many local ablation technologies based on thermal damage have been used in the treatment of locally advanced @entity3123 (LAPC) and borderline resectable @entity3123 (BLRPC). However, they are associated with major complications because of possible vascular and ductal damage. Irreversible electroporation (IRE) is a nonthermal ablation technology that seems safe near vital vascular and ductal structures. IRE could be used as exclusive treatment of LAPC (en situ to IRE) after induction chemotherapy In BLRPC, surgery is not really radical in 6% of @entity1 (microscopic residual) and local recurrences occur in 11-42% of apparent radical resections. IRE could be used as margin accentuation to increase posterior margin during radical surgery in BLRPC. Our outcomes are safety, time to progression. Secondary outcomes are overall survival, pain control and quality of life. We are performing a prospective evaluation of @entity1 undergoing IRE for LAPC or BLRPC since July 2014. We have included @entity1 with non-metastatic LAPC with maximum size <= 4  cm (en situ to IRE) and @entity1 with BLRPC (complementary IRE). We have performed induction chemotherapy in both groups. After treatment, @entity1 were evaluated on days 1, 2, 4, 7, 14, 21, 30, 60 and 90 with amylase and lipase serum and abdominal drainage test. Based on Ethics Committee's request, follow-up imaging was performed at the 10th  day for safety evaluation, at 30, 60 and 90  days for response evaluation and then every 3  months. Seven @entity1 (two @entity1 and five @entity1 ) underwent IRE. Two @entity1 had LAPC and received en situ to IRE. In five @entity1 affected by BLRPC we performed IRE and pancreatic head resection. In all @entity1 , intraoperative imaging confirmed that the treatment of the whole @entity5 volume was complete. All seven @entity1 demonstrated nonclinically relevant elevation of their amylase and lipase, which returned normal at 5  days postprocedure. No @entity1 showed evidence of clinical @entity788 or @entity292 . No major complications were recorded. @entity1 with LAPC died of distant metastases 6  month after treatment. At 3- and 6-month follow-up, all @entity1 with BLPRC were alive and disease free. Only one @entity1 has already reached 9-month follow-up and is alive and disease free. Our results are only preliminary. However, IRE ablation of LAPC and BLRPC seems a safe and feasible treatment.

Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient', 'men'] @entity3123 :: ('MESH:C562463', 'Disease') :: ['pancreatic carcinoma'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity292 :: ('MESH:D005402', 'Disease') :: ['fistula']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic adenocarcinoma']
